Introduction {#S1}
============

Renal medullary carcinoma is a rare but highly aggressive form of renal cancer primarily occurring in adolescents and young adults with sickle cell trait. First described as a distinct entity by Davis et al. in 1995, it was termed as the 7^th^ sickle cell nephropathy given its almost exclusive association with sickle cell trait \[[@R1]\]. However, rare cases have also been reported in patients with other hemoglobinopathies (e.g. SC or SS sickle cell disease) \[[@R2]\]. Patients with renal medullary carcinoma typically present at a young age and are often symptomatic and with advanced disease; despite surgery and chemotherapy, their disease progresses quickly with a dismal prognosis \[[@R2]--[@R7]\]. Beyond the strong clinical association with sickle cell trait, the underlying biology of this aggressive tumor is poorly understood. Consequently, the definition and pathologic diagnostic criteria for renal medullary carcinoma have remained somewhat controversial. As a medulla-centered tumor, it often exhibits significant clinicopathologic overlap with other subtypes of high-grade renal cell carcinoma involving renal medulla such as collecting duct carcinoma, hereditary leiomyomatosis renal cell carcinoma or fumarate hydratase-deficient renal cell carcinoma, unclassified renal cell carcinoma, and urothelial carcinoma of the renal pelvis \[[@R8]--[@R13]\].

In recent years, loss of SMARCB1 (also known as INI1 or BAF47) expression, has emerged as a key diagnostic feature of renal medullary carcinoma \[[@R14]--[@R16]\]. SMARCB1 protein is a core subunit of the switch/sucrose nonfermentable (SWI/SNF) chromatin remodeling complexs, which are essential modulators of a variety of cellular processes such as DNA damage repair, DNA replication, proliferation, and differentiation \[[@R17]\]. Loss of SMARCB1 expression has been described in a variety of malignant neoplasms with a propensity for rhabdoid cytomorphology, including pediatric renal and extrarenal malignant rhabdoid tumors, atypical teratoid/rhabdoid tumors of the central nervous system, epithelioid sarcomas, renal medullary carcinoma, and an increasing number of other malignant tumors \[[@R18], [@R19]\]. However, compared to tumors such as malignant rhabdoid tumors in which biallelic *SMARCB1* alterations have been demonstrated \[[@R20]\], the mechanism underlying SMARCB1 protein loss in renal medullary carcinoma has remained relatively elusive: no *SMARCB1* mutations were found in a small number of cases that were sequenced, while copy number or loss of heterozygosity analysis revealed only hemizygous loss \[[@R15], [@R16]\]. Calderaro et al. recently reported novel balanced translocations disrupting *SMARCB1* as the second-hit in 4 of the 5 studied cases \[[@R21]\]. In that study, all 4 cases with *SMARCB1* translocations occurred in patients with sickle cell trait or disease and involved various fusion partners, whereas the remaining case harbored a homozygous deletion of *SMARCB1* and presented in a patient with normal hemoglobin. These results led the authors to suggest that translocations disrupting *SMARCB1* is the hallmark recurrent genetic alterations in renal medullary carcinoma.

On the other hand, with the increasing utilization of next-generation sequencing in research and clinical samples, somatic *SMARCB1* mutations are occasionally detected in other subtypes of renal cell carcinoma. For example, somatic mutations of *SMARCB1* are found in about 1--2 % of clear cell, papillary, or chromophobe renal cell carcinoma cases in a few large cohorts with comprehensive genomic characterization \[[@R22]--[@R24]\]. We have also previously reported *SMARCB1* somatic mutations in 3 of 62 (5%) cases of high-grade renal cell carcinoma with unclassified histology and no clinical history of sickle cell trait/disease, but interestingly, all these 3 cases had retained SMARCB1 protein despite the presence of mutations \[[@R12]\]. Nonetheless, loss of SMARCB1 protein has been described in rare cases that display medullary morphology but occur in patients without hemoglobinopathies \[[@R10], [@R25], [@R26]\]. Meanwhile, a complete loss or decreased expression of SMARCB1, as well as a focal and weak staining pattern, have been reported in some cases of collecting duct carcinoma \[[@R27], [@R28]\]. It is unknown whether there were any underlying *SMARCB1* molecular alterations in these non-medullary cases with a loss of SMARCB1 expression.

To interrogate the molecular mechanisms underlying the loss of SMARCB1 expression in renal medullary carcinoma, we assembled a cohort of 20 cases with detailed clinicopathologic information. We investigated the status of *SMARCB*1 locus using a 3-color fluorescence in situ hybridization (FISH) assay complemented by targeted next-generation sequencing platforms that detect somatic mutations in many cancer-related genes including *SMARCB1*. We further analyzed clinicopathologic correlations in tumor subsets with distinctive molecular alterations.

Materials and Methods {#S2}
=====================

Case selection and histologic assessment {#S3}
----------------------------------------

Patients with a diagnosis of renal medullary carcinoma rendered at two institutions between 1996 and 2017 were retrospectively identified from the institutional databases, respectively. The study was approved by the respective institutional review board of each institution. All cases had been reviewed to confirm the pathologic diagnosis of renal medullary carcinoma, including corroborating the status of sickle cell trait or other hemoglobinopathies and performing additional immunohistochemical stains to exclude recently recognized entities that were not considered in the initial diagnosis.

All cases included in the current study (n=20) had archival tissue available for at least one method of molecular analysis (FISH or sequencing). The clinical and follow-up information was obtained from prospectively maintained institutional databases or electronic medical records. Nine of the 20 cases were included in a previous study \[[@R6]\].

All available archival materials were reviewed, and the morphologic features of each case were recorded. These included growth patterns (reticular/yolk-sac like and cribriform, tubulopapillary, infiltrating tubules/cords/individual cells, and solid sheets), stromal changes, rhabdoid cytology, inflammatory infiltrates, and the presence or absence of drepanocytes, necrosis, and mucin. As reticular or yolk sac tumor-like growth and cribriform pattern often overlapped, these were combined as one architectural pattern group.

Immunohistochemical analysis of SMARCB1 and OCT4 {#S4}
------------------------------------------------

Immunohistochemistry was performed on 4-μm-thick sections from representative formalin-fixed, paraffin-embedded tissue blocks utilizing mouse monoclonal antibodies SMARCB1/INI1 (Clone 25/BAF47, dilution 1:200, BD Bioscience) and OCT4 (Clone MRQ10, dilution 1:200, Cell Marque) and an automated system (Benchmark Ultra, Roche). SMARCB1/INI1 staining was scored as retained or lost when compared to internal positive control cells (endothelial/stromal cells and lymphocytes). OCT4 staining was scored as 0 (negative), 1+ (positive in \< 10% tumor cells), 2+ (positive in 10--50% tumor cells) or 3+ (positive in \>50% tumor cells).

FISH analysis {#S5}
-------------

FISH analysis was performed on paraffin sections (4 μm) using a 3-color probe mix as previously described \[[@R6]\]. Briefly, bacterial artificial chromosome clones spanning *5'SMARCB1* (RP11--248J22 and RP11--1112A23, labeled as red), *SMARCB1* (RP11--71G19, labeled as orange), and 3'*SMARCB1* (RP11--80O7 and RP-11--76E8, labeled as green) were used as probes. Probe labeling, tissue processing, hybridization, post-hybridization washing, and fluorescence detection were performed according to standard laboratory procedures. Slides were scanned using a Zeiss Axioplan 2i epifluorescence microscope equipped with MetaSystems (Waltham, MA) imaging system. Metafer and VSlide modules within the system were used to generate virtual images of H&E and DAPI-stained sections. In all, corresponding H&E sections assisted in localizing tumor region.

To assess the quality of hybridization and possible intratumoral heterogeneity, the entire section was scanned under 63x objective. Following the initial scan, representative regions were imaged through the depth of the tissue (compressed/merged stack of 12 z-section images taken at 0.5-micron intervals), and at least 10 images per representative region captured. Signal counts (scoring) were performed on captured images. For each case, a minimum of 3 distinct regions (representative of the distinct/major signal pattern) were selected and 50 discrete nuclei were scored. To derive cut-off values (mean percent nuclei plus three standard deviations), five normal/benign renal tissue sections or a minimum of 50 nuclei were also scored in each case. The cut-off value was set at 10% for *SMARCB1* translocation (clear split/separation of *SMARCB1* in at least one allele), 50% for hemizygous loss \[*SMARCB1* (orange)*=1*, *5'SMARCB1* (red) and/or *3'SMARCB1* (green) ≥ 1\], and 10% for homozygous loss \[*SMARCB1*=0, *5'SMARCB1* and/or *3'SMARCB1* ≥ 1\].

Targeted sequencing analysis {#S6}
----------------------------

All H&E slides were reviewed to select representative areas of the tumors with sufficient tumor content. DNA was extracted from the macro-dissected tumor and matched normal samples using QIAamp DNA FFPE Tissue Kit or EZ1 Advanced XL system (Qiagen) according to the manufacturer's instructions. DNA samples of 9 cases were subjected to MSK-IMPACT, a hybridization capture-based NGS assay for targeted deep sequencing of all exons and selected introns of ≥ 410 or 468 cancer-related genes \[[@R29]\]. In cases with paired normal tissue/blood DNA samples, somatic mutations were called after private germline single-nucleotide variants detected in the paired normal sample were appropriately filtered out. The functional impact of detected mutations was categorized as oncogenic/likely oncogenic and variants of unknown significance using OncoKB ([http://oncokb.org](http://oncokb.org/)), a precision oncology knowledge base maintained at MSKCC \[[@R30]\]. The allele-specific copy number analysis of MSK-IMPACT data was conducted using open-source FACETS (Fraction and Allele-Specific Copy Number Estimates from Tumor Sequencing) tool \[[@R31]\].

Tumor tissue samples of 5 cases from Montefiore Medical Center were subjected to the NexCourse® Complete test (Genoptix, Carlsbad, CA), a capture-based next-generation sequencing platform that detected mutations in targeted regions of key genes recurrently mutated in various human cancers (<https://genoptix.com/test-menu/nexcourse-complete>).

High-resolution single nucleotide polymorphism (SNP) array analysis {#S7}
-------------------------------------------------------------------

Genome-wide DNA copy number alterations and allelic imbalances were analyzed by SNP-array using Affymetrix OncoScan FFPE Assay (Affymetrix, CA) according to the manufacturer's guidelines as previously described \[[@R32]\]. Assay data were analyzed by OncoScan Console software (Affymetrix) and OncoScan Nexus Express software (BioDiscovery, CA, USA) using Affymetrix TuScan algorithm. All array data were also manually reviewed for subtle alterations not automatically detected by the software.

Statistical analysis {#S8}
--------------------

The statistical significance of clinicopathologic features between subsets of renal medullary carcinoma cases was determined using Fisher's exact test or Mann-Whitney U test (age and tumor size). Statistical significance was defined as a *P*-value \< 0.05.

Results {#S9}
=======

Clinical features {#S10}
-----------------

The clinical features of the study cases are summarized in [Table 1](#T1){ref-type="table"}. All 20 patients had a clinically documented diagnosis of sickle cell trait. Of the 19 patients who self-reported race, 15 (79%) were black or African-American. The mean age of patients was 26 years (range 7--61 years), with a male to female ratio of 3:2. Patients most often presented with flank or abdominal pain (12/20, 60%) and/or gross hematuria (8/20, 40%). Initial symptoms in 4 patients (20%) were related to metastases, including shortness of breath resulting from lung or pleural metastases in 3 patients and skin nodules in 1. In only one case the renal mass was found incidentally through imaging work-up for unrelated complaints. The mean tumor size was 6.0 cm (range 2.7--8.9 cm), and the majority were right-sided (14/20, 70%). Metastases were detected in 14 (70%) patients at initial diagnosis. Nine patients (45%) underwent nephrectomy and the others had diagnostic biopsies either from the kidney (n=2) or metastatic sites (n=9). With a median follow-up time of 9 months (range 1--78 months), 75% (15/20) of patients had died of disease, 25% (5/20) were alive with disease, and 4 of these 5 patients were subsequently lost to follow-up.

Morphological and immunohistochemical features {#S11}
----------------------------------------------

Among the 9 nephrectomies (Cases \# 1--9) ([Fig. 1](#F1){ref-type="fig"}), a range of architectural patterns was seen ([Table 2](#T2){ref-type="table"}). Reticular (or yolk sac tumor-like glands) and cribriform patterns represented the dominant architectural component in 6 (67%) cases, whereas the remaining 3 (33%) tumors mainly consisted of solid sheets or nests of cells. The pattern of infiltrating tubules, cords, or individual cells in a desmoplastic stroma was at least focally present in all cases (100%), but not as a dominant pattern. Tubulopapillary growth (including micropapillary pattern), as a minor component, was found in 4 (44%) cases.

In comparison, core or small biopsies of the primary renal mass (n = 2) and metastatic sites (n = 9) ([Fig. 2](#F2){ref-type="fig"}) revealed infiltrating tubules/solid cords/individual cells in a desmoplastic stroma as the dominant pattern in 5 of 11 cases (45%). The dominant pattern in 3 (27%) biopsy cases was solid (small or large nests), while the other 3 (27%) exhibited a predominantly reticular growth.

The rhabdoid cytologic feature was extensive in 9 (50%) tumors and focal in 8 (40%) ([Fig. 1c](#F1){ref-type="fig"} and [Fig. 2d](#F2){ref-type="fig"}). Intraluminal or cytoplasmic mucin was identified in 6 (30%) cases ([Fig. 1f](#F1){ref-type="fig"} and [Fig. 2b](#F2){ref-type="fig"}). While desmoplastic stroma was present in all cases, stromal myxoid change was noted in 9 cases (45%) ([Fig. 1f](#F1){ref-type="fig"} and [Fig. 2a](#F2){ref-type="fig"}). Necrosis was present in 14 (70%) cases. The neutrophil-rich inflammatory infiltrate was present in 10 of 11 (89%) primary tumors ([Fig. 1b](#F1){ref-type="fig"}) and 4 of 9 (44%) metastases. Although drepanocytes in small vessels were identified in all 9 (100%) nephrectomy specimens, it was difficult to be certain about their presence in 7 of 11 (64%) biopsy samples, mainly due to a paucity of small vessels with discernible red blood cells.

By immunohistochemistry ([Fig. 3](#F3){ref-type="fig"} and [Table 2](#T2){ref-type="table"}), all 20 cases showed a loss of nuclear expression of the SMARCB1 protein. OCT4 nuclear immunoreactivity was detected in 9 cases, including 6 (30%) with moderate to strong staining (2+ or 3+) and 3 with only focal staining (1+).

FISH and mutational analysis {#S12}
----------------------------

All cases (n = 20) were analyzed by FISH ([Table 3](#T3){ref-type="table"}). Compared to the diploid pattern in the control (normal blood leukocytes) ([Fig. 4a-b](#F4){ref-type="fig"}) or internal control cells (stromal and inflammatory cells), the majority of cells in 11 (55%) tumors showed the split of red-orange-green signals, indicating the presence of *SMARCB1* rearrangement ([Fig. 4c-f](#F4){ref-type="fig"}). This was accompanied by a concurrent hemizygous loss of *SMARCB1* and neighboring regions in the other allele in the vast majority of cases (n =10) ([Fig. 4c-e](#F4){ref-type="fig"}). The remaining case (\#6) was dominated by tumor cells with two sets of split green and red signals ([Fig. 4f](#F4){ref-type="fig"}). Interestingly, the split signals in cases with *SMARCB1* rearrangement showed various patterns, including one case with inversion ([Fig. 4e](#F4){ref-type="fig"}), suggesting the presence of potentially different breakpoints within *SMARCB1* and is in line with various fusion partners previously identified \[[@R21]\].

Six (30%) cases exhibited homozygous loss of *SMARCB1* (orange) and, to a variable extent, the adjacent regions (red and green signals) ([Fig. 4g-i](#F4){ref-type="fig"}). The remaining 3 (15%) cases showed a diploid pattern ([Fig. 4j](#F4){ref-type="fig"}), without detectable structural or copy number alterations involving *SMARCB1* locus despite the loss of protein expression.

Targeted sequencing was performed in 14 cases and all identified mutations are summarized ([Supplementary Table 1](#SD1){ref-type="supplementary-material"}). In one of the 3 FISH-negative cases, sequencing detected a somatic truncating mutation of *SMARCB1* ([Table 3](#T3){ref-type="table"}). Aside from *SMARCB1*, somatic oncogenic or likely oncogenic mutations of *TSC2*, *TP53*, *EP300*, and *JAK2* etc. were detected, but none of these was recurrent in the cohort. Importantly, in 9 of 14 (64%) cases, there were no somatic oncogenic mutations detected by our targeted sequencing panels, consistent with the notion that SMARCB1 protein loss is the crucial molecular alterations driving the tumor development.

The allele-specific copy number analysis using FACETS tool revealed copy number changes in 8 cases ([Table 3](#T3){ref-type="table"} and [Fig. 5a-c](#F5){ref-type="fig"}). Among these, 22q loss was the most frequent alterations. Interestingly, while 22q loss was consistently identified in cases with homozygous loss by FISH, the detection of a loss in 22q or *SMARCB1* locus was less reliable in cases with hemizygous loss, presumably due to a high percentage of non-neoplastic cells (e.g. inflammatory and stromal cells) masking the low-level copy number changes. Beyond 22q, there was no consistent copy number alteration pattern identified. FACETS analysis did not identify *SMARCB1* translocation.

For case \#6, to differentiate the possibility of two independent translocations vs. genomic doubling of one translocation event with concurrent hemizygous loss, we performed high-density SNP array analysis and found that this tumor predominantly consisted of a tetraploid clone, whereas chromosome 22q (including *SMACRB1* locus) remained as diploid and showed loss of heterozygosity ([Fig. 5d](#F5){ref-type="fig"}). These findings support that a genome-wide doubling occurred in this tumor after the *SMARCB1* translocation and concurrent hemizygous loss. In this predominantly tetraploid genome, there were also additional losses of one or two copies of other chromosomes, including 15 as diploid and 3, 10, 12, and 16 as triploid ([Table 3](#T3){ref-type="table"}). These findings were further confirmed by FISH analysis using centromere probes of multiple chromosomes (data not shown).

Taken together, FISH and mutational analyses revealed mechanisms of biallelic inactivation of *SMARCB1* in 17 of 20 (85%) RMC cases, either via concurrent hemizygous loss and translocation disrupting *SMARCB1* or by homozygous loss ([Fig. 5e](#F5){ref-type="fig"}). Among the remaining 3 cases, one had a *SMARCB1* somatic mutation without accompanying copy number change detectable by FISH. In the other 2 cases, SMARCB1 protein loss was likely due to aberrations other than mutational, copy number, or structural alterations.

Correlation between clinicopathologic and molecular features {#S13}
------------------------------------------------------------

We further examined whether there were any clinicopathologic features of these cases associated with the different mechanisms of SMARCB1 loss, particularly for the two main molecular subsets, tumors with *SMARCB1* translocation and hemizygous loss vs. those with homozygous loss ([Table 4](#T4){ref-type="table"}). Interestingly, among all the parameters assessed, the dominant architectural pattern (reticular and cribriform growth vs. solid growth) was the only feature exhibiting a significant correlation with these two molecular subgroups (p=0.03). Tumors with *SMARCB1* translocation were more likely to show reticular and cribriform pattern (64% vs 17%), whereas tumors with *SMARCB1* homozygous loss were significantly enriched for a solid growth pattern (83% vs 9%).

Discussion {#S14}
==========

Renal medullary carcinoma is a rare but devastating subtype of renal cancer that is almost exclusively associated with sickle cell trait and rarely other hemoglobinopathies. While the biology of its pathogenesis largely remains unclear, the high prevalence of SMARCB1/INI1 protein loss in these cases examined by recent studies suggests it to be a critical molecular alteration that drives tumor development \[[@R14]--[@R16]\]. With the recent discovery of translocations disrupting *SMARCB1* reported by Calderaro et al. in 4 cases of renal medullary carcinoma \[[@R21]\], we sought to clarify the mechanisms of SMARCB1 loss in 20 well-characterized cases, to our knowledge the largest cohort of renal medullary carcinoma with molecular characterization. This cohort exhibited clinicopathologic features that are in line with previously reported series, and our molecular analysis emphasized the integration of different methods to elucidate alterations that might have evaded routine mutational or copy number analysis.

All cases in our study cohort indeed showed SMARCB1 protein loss. We demonstrate that distinct molecular mechanisms underlying the loss of SMARCB1 protein expression in renal medullary carcinoma, and biallelic inactivation of SMARCB1 occur in a large majority of cases. The combined translocation and hemizygous loss was the most common mechanism of SMARCB1 loss detected, accounting for 55% of the cohort and representing a relatively unique mechanism that has not been well described in other *SMARCB1*-deficient tumors. Meanwhile, homozygous deletion involving *SMARCB1* and various neighboring regions on 22q did occur in 30% of patients in this cohort, all of whom had sickle cell trait and classic clinicopathologic presentation of renal medullary carcinoma. In comparison, somatic mutation of *SMARCB1* was detected uncommonly, accounting for only 1 case (5%) in this cohort. Interestingly, the complete loss of SMARCB1 protein expression in about 15% of cases was not explained by translocation, copy number alterations, or mutations, suggesting the presence of additional molecular mechanisms, such as epigenetic and/or other regulatory mechanisms.

Moreover, there were no recurrent somatic oncogenic mutations detected in all other cancer-related genes included in the targeted next-generation sequencing panels utilized in our study. The non-recurrent somatic mutations such as *TSC2*, *TP53*, and *EP300*, while being pathogenic, more likely represent additional or later molecular alterations occurring in individual cases. We further elucidated copy number changes occurring in the remainder of the genome and identified additional gains and losses. We showed that genomic doubling can occur as a later event in renal medullary carcinoma, which potentially serves as a mechanism to increase the complexity of genomic aberrations. Taken together, our findings validate the central role of *SMARCB1* inactivation in the pathogenesis of renal medullary carcinoma and clarify the different molecular mechanisms underlying this process.

Recent comprehensive molecular studies of other SMARCB1-deficient tumors such as atypical teratoid/rhabdoid tumors, extra-cranial malignant rhabdoid tumors, and epithelioid sarcoma, have revealed significantly different molecular characteristics and intertumoral heterogeneity among these tumors \[[@R33]--[@R35]\]. Johann et al. identified three distinct molecular subtypes of atypical teratoid/rhabdoid tumors, which not only show very different epigenetic features and gene expression patterns, but are also associated with differences in patient demographics, tumor location, and types of *SMARCB1* alterations \[[@R34]\]. For example, broad *SMARCB1* deletions were observed in 77% of the ATRT-TYR tumors, whereas focal *SMARCB1* deletions were more prevalent in the ATRT-MYC subgroup (79%). It is interesting to note that a small percentage of atypical teratoid/rhabdoid tumors also lack detectable *SMARCB1* DNA aberrations despite protein loss \[[@R34]\]. Previously, altered miRNA expression has been shown as an epigenetic mechanism to regulate SMARCB1 expression in epithelioid sarcoma \[[@R36], [@R37]\].

Although epigenetic and transcriptional data are very limited in renal medullary carcinoma, the findings from atypical teratoid/rhabdoid tumors raise an interesting question of whether there could be additional differences among renal medullary carcinomas with distinct molecular mechanisms of inactivating *SMARCB1*, particularly between the two main subgroups with either translocation or homozygous deletion. In the current cohort, while most clinicopathologic features were indistinguishable between these molecular subgroups, we did observe a significant difference in their dominant morphologic architectural patterns. The cases harboring translocation mainly displayed reticular or cribriform growth, the relatively distinctive features of renal medullary carcinoma when compared to collecting duct or fumarate hydratase-deficient renal cell carcinoma \[[@R13]\], whereas the cases with homozygous deletion predominantly showed solid sheets or nests. Additional studies are needed to further test this association and investigate the possibility of biologic or molecular differences among renal medullary carcinomas with distinct mechanisms inactivating *SMARCB1*. Our analysis also suggests that there are variations in both translocation patterns and the extent of homozygous deletion, which might add additional levels of complexity to the observed morphologic divergence and overlap between the two molecular subgroups. Moreover, one patient (case \#9) in the cohort had an exceptionally long period of survival (78 months) before being lost to follow-up. This tumor lacked detectable structural or mutational aberrations but was morphologically indistinguishable from other cases.

Largely due to tissue constraints, we were not able to pursue fusion partners of *SMARCB1* translocation or explore the alterations at transcriptional and epigenetic levels in the three subsets of renal medullary carcinoma with distinctive mechanisms of inactivating *SMARCB1*. Further collaborative investigation in this regard would be essential to shed light on its pathogenesis and discover therapeutic approaches for this aggressive disease.

The morphologic spectrum we observed in this cohort is consistent with what has been described for renal medullary carcinoma and highlights a few important issues for the differential diagnosis. First, in nephrectomy specimens, the combined reticular/yolk sac-like and cribriform patterns were found to be dominant in the majority (67%) of cases. The remaining cases were frequently dominated by solid sheets or nests, reflecting the potentially different mechanisms inactivating *SMARCB1* based on our analysis. The infiltrating tubules, cords and individual cells in a desmoplastic stroma, a pattern commonly associated with collecting duct carcinoma, while universally present in all cases, did not present as a dominant pattern. In contrast, in biopsies, particularly core biopsies, probably due to the difficulty of appreciating certain architectural patterns (e.g. reticular), most cases appeared to fulfill the description of poorly-differentiated adenocarcinoma and could easily lead to a diagnosis of collecting duct carcinoma. In a similar fashion, cases with solid growth pattern in small biopsies could closely mimic high-grade urothelial carcinoma. Although rhabdoid cytology can be a very helpful feature in small biopsies to raise a suspicion for renal medullary carcinoma, it was not apparent in a subset of cases, and may also occasionally present in metastatic carcinomas involving the kidney. Rhabdoid cells could also be mistaken as suggesting plasmacytoid features of urothelial carcinoma. Drepanocytes or sickled red blood cells, while almost always visible in nephrectomies and very helpful for considering medullary carcinoma, could be difficult to identify in biopsies mainly due to a paucity of evident vascular spaces in these small specimens. The neutrophil-rich inflammatory infiltrate was present in the vast majority of primary tumors but was much less notable at metastatic sites. Additionally, mucin, stromal myxoid or desmoplastic changes sometimes provided non-specific, yet helpful clues for considering a diagnosis of renal medullary carcinoma in suspicious clinical contexts. By immunohistochemistry, all the cases in our cohort showed SMARCB1 protein loss, whereas OCT4 staining was much more variable with only 30% cases with moderate to strong immunoreactivity.

Aside from collecting duct carcinoma and high-grade urothelial carcinoma of upper tract, other entities that enter in the differential diagnoses for renal medullary carcinoma include fumarate hydratase-deficient, *ALK* rearrangement-associated, high-grade unclassified renal cell carcinoma, metastatic poorly-differentiated carcinoma secondarily involving kidney, and other SMARCB1-loss tumors. With the expanding histologic spectrum of hereditary leiomyomatosis renal cell carcinoma and fumarate hydratase-deficient renal cell carcinoma, we now recognize that these tumors can exhibit growth patterns indistinguishable from collecting duct carcinoma or show features mimicking renal medullary carcinoma, such as sieve-like or cribriform areas and mixed growth patterns \[[@R11], [@R13], [@R38]\]. Therefore, performing ancillary studies including fumarate hydratase and/or 2-succino-cysteine immunohistochemistry in cases raising concerns for these tumors is very important for distinguishing them from renal medullary carcinoma. In this setting, sickle cell trait can be a red herring and leads to an erroneous diagnosis. We excluded one such case in the re-review process of this study, a 27-year-old man with sickle cell trait but had a tumor exhibiting histologic features highly suspicious for fumarate hydratase-deficient renal cell carcinoma. This case was encountered before the pathologic features of hereditary leiomyomatosis renal cell carcinoma were recognized, and the additional studies we did showed diffuse immunopositivity for 2-succino-cysteine (nuclear and cytoplasmic staining) and a loss of fumarate hydratase, but retention of SMARCB1.

*ALK* rearrangement-associated RCC represents an emerging group of tumors that harbor *ALK* fusions. Several fusion partners have been identified, including *VCL*, *TPM3*, *EML4*, *STRN*, and *HOOK1* \[[@R39]--[@R44]\]. Among these, tumors with *VCL-AL*K fusion have been identified in patients with sickle cell trait and consist of sheets of polygonal or spindle cells with eosinophilic cytoplasm, large vesicular nuclei with prominent nucleoli, frequent intracytoplasmic vacuoles, and lymphocytic inflammatory infiltrate \[[@R39], [@R40], [@R42]\]. These tumors have retained SMARCB1 expression and appear to be less aggressive than renal medullary carcinoma. But given the small number of reported cases, their biologic behavior and relationship with renal medullary carcinoma await further investigations. The identification of *ALK*-rearrangement is becoming increasingly important as there is now growing evidence that these tumors can respond to ALK-directed therapy, which otherwise would not be considered for patients with advanced renal cancer \[[@R45]\].

Naturally, excluding renal medullary carcinoma is also important before diagnosing a high-grade unclassified renal cell carcinoma with imitating histologic features. At metastatic sites, including PAX8 and SMARCB1 staining in cases with suspicious histomorphology and/or clinical features (presence of renal mass or sickle cell trait) usually will be very helpful to distinguish renal medullary carcinoma from other poorly differentiated tumors. In this scenario, distinguishing renal medullary carcinoma from SMARCB1-loss tumors originating from other sites could be very difficult and heavily dependent on clinical correlations and PAX8 stain in the presence of a renal mass. It is also worth noting that malignant rhabdoid tumor of the kidney can rarely occur in older children and may display PAX8 immunoreactivity \[[@R46], [@R47]\]. The clinicopathologic features of these cases would significantly overlap with those of renal medullary carcinomas in children, and it will be particularly diagnostically challenging if the tumor exhibits a solid growth pattern. Moreover, extremely rare cases of malignant rhabdoid tumor of the kidney have also been reported in adults \[[@R48]\]. In these rare settings, how to distinguish renal medullary carcinoma from malignant rhabdoid tumor of the kidney and the importance of sickle cell trait/hemoglobinopathy remain to be further clarified.

Together with recent studies of renal medullary carcinoma, our analysis strongly supports SMARCB1 protein loss as the main molecular feature and driving force underlying the development of this aggressive disease. However, given the increasingly detected *SMARCB1* mutations and very rarely protein loss in other types of renal cell carcinoma, the roles of *SMARCB1* alterations in specific biologic contexts of different renal cancer subtypes need to be investigated and compared. For instance, it will be very interesting to examine the mechanisms of *SMARCB1* inactivation in unclassified renal cell carcinoma with medullary phenotype and rare tumors with loss of SMARCB1 protein by immunohistochemistry in patients without hemoglobinopathies \[[@R10], [@R26]\].

In summary, we performed an integrated analysis of 20 renal medullary carcinoma cases to delineate the molecular mechanisms underlying the loss of SMARCB1 expression and demonstrated biallelic inactivation of *SMARCB1* in a large majority of cases. This most frequently develops via hemizygous loss and concurrent translocation disrupting *SMARCB1* locus, but homozygous deletion of *SMARCB1* also represents an important molecular mechanism in patients with sickle cell trait. Additionally, inactivation of *SMARCB1* in renal medullary carcinoma may occur via somatic mutation and/or other yet to be defined mechanisms. We also identified an intriguing association between solid growth pattern and homozygous deletion whereas cases harboring translocation and hemizygous loss more commonly displayed reticular and cribriform architectures. These findings validate the central role of *SMARCB1* inactivation and provide new insights into the pathogenesis of renal medullary carcinoma.
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![Renal medullary carcinoma in nephrectomy specimens showed reticular/yolk sac tumor-like (**a**), cribriform (**b**), solid sheets (**c**), infiltrating tubules and individual cells in a desmoplastic stroma (**d**), and tubulopapillary (**e**) architectural patterns. Mucin and stromal myxoid changes are prominent in some cases (**f**). Insets, (b) neutrophil-rich inflammatory infiltrate, (c) rhabdoid feature.](nihms-1523944-f0001){#F1}

![Renal medullary carcinoma revealed by biopsies at metastatic sites displayed infiltrating tubules/solid cords/individual cells in a desmoplastic and myxoid stroma (**a**), reticular/cribriform glands with cytoplasmic mucin in desmoplastic stroma (**b**), solid sheets/nests (**b**), and micropapillary features and individual cells (**d**). Rhabdoid cytologic feature was prominent in some cases (d).](nihms-1523944-f0002){#F2}

![SMARCB1 protein expression was lost in tumor cells while the nuclear staining was retained in internal control cells (**a**). Nuclear immunoreactivity to OCT3/4 was observed in a subset of cases, some with strong positivity (**b**) and others with focal weak staining (**c**).](nihms-1523944-f0003){#F3}

![Three-color FISH analysis of *SMARCB1* (22q11) and neighboring regions. Normal control blood leukocytes at interphase (**a**) and metaphase (**b**), representative renal medullary carcinoma cases with hemizygous loss (loss of one set of red-orange-green signals) and concurrent translocation (split of the other set of signals) (**c-d**), case \#12 with hemizygous loss and concurrent inversion in the other allele (**e**), case \#6 with two sets of split signals (**f**), representative cases with homozygous deletion (**g-i**), and a representative case showing diploid pattern without structural and copy number alteration (**j**). The arrowhead in (i) marks a tumor nucleus that completely lost all signals whereas the arrow marks the nucleus of an internal control cell.](nihms-1523944-f0004){#F4}

![Allele-specific copy number changes revealed by FACETS (fraction and copy number estimates from tumor sequencing) analysis showed flat genome (**a**), 22q loss (**b**), or additional gains and losses (**c**). The integer copy number (copy number call corrected for tumor purity and ploidy) is plotted on the y-axis. Diploid corresponds to n = 2. Chromosomes 1--22 are plotted on the x-axis. Black line - total copy number, red line -- minor/B allele. (a) case \#17, (b) case \#18, (c) case \#16. Genome-wide copy number changes in case \#6 by SNP-array analysis (**d**). All chromosomes are color-coded. For copy number log-ratio (top panel), diploid corresponds to y = 0. For B-allele frequency (bottom panel), separation of dots from baseline indicates allelic imbalance. The arrow points to chromosome 22q. Pie chart summarizes the *SMARCB1* alterations detected in 20 cases of renal medullary carcinoma using integrated analysis (**e**).](nihms-1523944-f0005){#F5}

###### 

Clinical characteristics of renal medullary carcinoma cases (n=20).

  Case \#   Age (yr)   Sex   Race      SCT   Presentations              Procedure       Side   Size (cm)   Stage at diagnosis   Metastatic site(s)                                      Systemic treatment   Outcome (f/u months)
  --------- ---------- ----- --------- ----- -------------------------- --------------- ------ ----------- -------------------- ------------------------------------------------------- -------------------- ------------------------------------------
  1         41         M     Black     Y     Right abdominal pain       Nx              R      5.6         III                  None                                                    Chemoradiation       DOD (23)
  2         12         M     Unknown   Y     Hematuria                  Nx              R      6.5         IV                   Vertebra and LNs                                        Chemotherapy         DOD (8)
  3         25         F     Other     Y     Hematuria                  Nx              R      6.5         III                  RP and mediastinal LNs                                  Chemotherapy         AWD (27)[\*](#TFN2){ref-type="table-fn"}
  4         46         M     Black     Y     Hematuria, back pain       Nx              R      5.7         I                    None                                                    Chemotherapy         DOD (3)
  5         7          F     Black     Y     Abdominal pain, vomiting   Nx              L      6           IV                   RPLN and soft tissue                                    Chemotherapy         DOD (24)
  6         23         F     Black     Y     Right flank pain           Nx              R      8.9         III                  Bones, lungs, pleura, pericardium, and breast           Chemotherapy         DOD (8)
  7         17         M     Other     Y     Hematuria, flank pain      Nx              R      5.5         IV                   RP LNs, lungs                                           Chemotherapy         AWD (13)[\*](#TFN2){ref-type="table-fn"}
  8         15         F     Black     Y     Hematuria, flank pain      Nx              R      9           IV                   Right lung, liver, RP LNs, pleura                       Chemotherapy         AWD (7)[\*](#TFN2){ref-type="table-fn"}
  9         13         M     Black     Y     Hematuria, flank pain      Nx              R      4           III                  None                                                    None                 AWD (78)[\*](#TFN2){ref-type="table-fn"}
  10        20         M     Black     Y     Flank pain, night fever    Renal bx        R      5.3         III                  RP LNs, lungs, liver, pleura                            Chemotherapy         DOD (10)
  11        22         M     Other     Y     Flank pain, hematuria      Renal bx        R      6.5         IV                   Liver, RP LNs, lungs                                    Chemotherapy         DOD (3)
  12        20         M     Black     Y     Left flank pain            Pleural bx      L      7           IV                   Lung, RP LNs                                            Chemotherapy         DOD (5)
  13        28         F     Black     Y     Skin nodules               Chest wall bx   R      5.9         IV                   LNs, skin, muscle, lungs, brain                         Chemotherapy         DOD (11)
  14        39         M     Black     Y     Weight loss, flank pain    LN bx           R      6.8         IV                   Mesenteric, RP, and inguinal LNs, spleen, liver, bone   Chemotherapy         DOD (14)
  15        27         F     White     Y     Left flank pain            RP bx           L      7.6         IV                   Liver, LNs, spine, lung                                 Chemotherapy         DOD (4)
  16        25         M     Black     Y     Incidental renal mass      Pleural bx      R      4           IV                   Pleura and lung                                         Chemoradiation       DOD (8)
  17        28         F     Black     Y     Cough, dyspnea             LN bx           R      3.2         IV                   Axillary LNs and lung                                   Chemotherapy         DOD (11)
  18        10         M     Black     Y     Cough, chest pain          LN bx           L      2.7         IV                   Lungs, liver, LNs                                       Chemotherapy         DOD (10)
  19        61         F     Black     Y     Hematuria                  LN bx           L      6.8         III                  RP LNs, liver, bone                                     Chemotherapy         AWD (8)
  20        34         M     Black     Y     Short of breath            Pleural bx      L      n/a         IV                   Pleura, RP LNs                                          None                 DOD (1)

SCT, sickle cell trait; Nx, nephrectomy; bx, biopsy; LN, lymph node; RP, retroperitoneal; AWD, alive with disease; DOD, dead of disease.

Patient subsequently lost to follow-up

###### 

Histological and immunohistochemical features (n=20). ^[†](#TFN4){ref-type="table-fn"}^

  Case \#   Reticular/ cribriform   Tubulo-papillary   Infiltrating tubules/cords in desmoplastic stroma   Solid sheets/nests   Rhabdoid       Mucin[\*](#TFN5){ref-type="table-fn"}   Inflam. infiltrates   Necrosis   Myxoid stroma   Drepano-cytes   SMARCB1 (IHC)   OCT4 (IHC)
  --------- ----------------------- ------------------ --------------------------------------------------- -------------------- -------------- --------------------------------------- --------------------- ---------- --------------- --------------- --------------- ------------
  **1**     Dominant                N                  Y                                                   N                    Not apparent   N                                       Neutrophil-rich       Y          N               Y               Loss            1+
  **2**     N                       N                  Y                                                   Dominant             Extensive      Y                                       Neutrophil-rich       Y          Y               Y               Loss            −
  **3**     N                       N                  Y                                                   Dominant             Extensive      N                                       Neutrophil-rich       Y          N               Y               Loss            −
  **4**     Dominant                N                  Y                                                   N                    Focal          Y                                       Neutrophil-rich       Y          Y               Y               Loss            −
  **5**     Dominant                Y                  Y                                                   N                    Extensive      Y                                       Neutrophil-rich       Y          Y               Y               Loss            −
  **6**     Dominant                Y                  Y                                                   Y                    Not apparent   Y                                       Minimal               Y          Y               Y               Loss            3+
  **7**     Dominant                Y                  Y                                                   N                    Extensive      N                                       Neutrophil-rich       Y          N               Y               Loss            2+
  **8**     N                       N                  Y                                                   Dominant             Extensive      N                                       Neutrophil-rich       Y          N               Y               Loss            −
  **9**     Dominant                Y                  Y                                                   N                    Not apparent   N                                       Neutrophil-rich       Y          N               Y               Loss            1+
                                                                                                                                                                                                                                                                        
  10        N                       N                  Dominant                                            N                    Focal          N                                       Neutrophil-rich       Y          N               IND             Loss            −
  11        N                       N                  Dominant                                            N                    Focal          N                                       Neutrophil-rich       Y          Y               IND             Loss            −
  12        Dominant                N                  Y                                                   N                    Focal          N                                       Minimal               N          N               Y               Loss            3+
  13        Y                       Y                  Dominant                                            N                    Focal          N                                       Neutrophil-rich       Y          Y               Y               Loss            −
  14        Y                       N                  Y                                                   Dominant             Focal          N                                       Lymphocytic           N          N               IND             Loss            2+
  15        Y                       N                  Dominant                                            N                    Extensive      N                                       Minimal               N          Y               IND             Loss            3+
  16        Dominant                N                  Y                                                   N                    Extensive      N                                       Neutrophil-rich       N          N               Y               Loss            −
  17        Y                       N                  Dominant                                            N                    Extensive      N                                       Neutrophil-rich       N          Y               IND             Loss            1+
  18        N                       N                  Y                                                   Dominant             Extensive      N                                       Lymphocytic           Y          N               IND             Loss            −
  19        N                       N                  Y                                                   Dominant             Focal          Y                                       Neutrophil-rich       Y          N               Y               Loss            −
  20        Dominant                N                  Y                                                   N                    Focal          Y                                       Minimal               N          Y               IND             Loss            3+

IND, indeterminate; NA, not available; IHC, immunohistochemistry.

Case \# 1-9 is nephrectomy specimen.

Mucin indicates cytoplasmic or intratubular mucin.

###### 

Molecular alterations detected by FISH, targeted sequencing and copy number analyses (n=20).

  Case \#   *SMARCB1* locus (FISH)                                             Known/likely oncogenic somatic mutations                                                                           Copy number changes (FACETS or SNP array)
  --------- ------------------------------------------------------------------ ------------------------------------------------------------------------------------------------------------------ ---------------------------------------------------
  1         Hemizygous loss & translocation                                    NA                                                                                                                 NA
  4         Hemizygous loss & translocation                                    None                                                                                                               Gain: 2q, 11q
                                                                                                                                                                                                  CN-LOH: 13p
  6         Hemizygous loss & translocation^[§](#TFN7){ref-type="table-fn"}^   None                                                                                                               Tetraploid genome[\*](#TFN8){ref-type="table-fn"}
                                                                                                                                                                                                  Loss (diploid): 22q, 15
                                                                                                                                                                                                  Loss (triploid): 3, 10, 12, 16
  7         Hemizygous loss & translocation                                    NA                                                                                                                 NA
  8         Hemizygous loss & translocation                                    None                                                                                                               NA
  12        Hemizygous loss & translocation                                    NA                                                                                                                 NA
  13        Hemizygous loss & translocation                                    NA                                                                                                                 NA
  15        Hemizygous loss & translocation                                    NA                                                                                                                 NA
  16        Hemizygous loss & translocation                                    *NSD1* p.E2550fs[\*](#TFN8){ref-type="table-fn"}14                                                                 Loss: 6q21, 9p, 13, 22q
                                                                                                                                                                                                  Focal gains: 6p21--22, 2q14, 12p13, 21q12
  17        Hemizygous loss & translocation                                    None                                                                                                               None
  20        Hemizygous loss & translocation                                    *TSC2* p.D1690Gfs[\*](#TFN8){ref-type="table-fn"}27                                                                NA
                                                                                                                                                                                                  
  2         Homozygous loss                                                    None                                                                                                               Deep loss: 22q11
  3         Homozygous loss                                                    None                                                                                                               NA
  5         Homozygous loss                                                    None                                                                                                               Loss: 22q, 5p (focal),12q (focal)
                                                                                                                                                                                                  Gain: 5q, 6, 7, 12
  14        Homozygous loss                                                    *RASA1* p.N1038fs                                                                                                  Deep loss: *SMARCB1* locus, Xp (focal)
                                                                                                                                                                                                  Loss: 7p (focal), 15p (focal)
                                                                                                                                                                                                  Gain: 7q, 8q
  18        Homozygous loss                                                    None                                                                                                               Loss: 22q, 16p13
                                                                                                                                                                                                  Tetraploid: 6p21--p22
  19        Homozygous loss                                                    NA                                                                                                                 NA
                                                                                                                                                                                                  
  9         Diploid                                                            None                                                                                                               NA
  10        Diploid                                                            *TP53* p.R337C                                                                                                     NA
                                                                               *EP300* c.3143--1_3143insT, null                                                                                   
  11        Diploid                                                            ***SMARCB1*** p.H68Qfs[\*](#TFN8){ref-type="table-fn"}                                                             NA
                                                                               *JAK2* p.E90[\*](#TFN8){ref-type="table-fn"}                                                                       
                                                                               LOC100131635[\*](#TFN8){ref-type="table-fn"}BCL6[\*](#TFN8){ref-type="table-fn"} dup. (ch3:187440242--187463515)   

NA, not available.

Majority cells showed a tetraploid genome, consistent with genomic doubling occurring after translocation and hemizygous loss.

SNP array analysis.

###### 

Correlations between clinicopathologic and molecular features.

  Clinicopathologic features         RMC with *SMARCB1* translocation and heterozygous loss (n=11)   RMC with *SMARCB1* homozygous loss (n=6)   *P*
  ---------------------------------- --------------------------------------------------------------- ------------------------------------------ ----------
  Median age (range)                 27 (15--46)                                                     19 (7--61)                                 0.42
  Male:female                        1.2:1                                                           1:1                                        \-
  Race-black                         9/11 (82%)                                                      4/5 (80%)                                  \-
  Sickle cell trait                  11/11 (100%)                                                    6/6 (100%)                                 \-
  Laterality-right                   8/11 (73%)                                                      3/6 (50%)                                  0.6
  Mean tumor size (range)            6.2 (3.2--9)                                                    5.9 (2.7--6.8)                             0.5
  Stage at diagnosis                                                                                                                            \-
   I                                 1 (9%)                                                          0                                          
   III                               2 (18%)                                                         2 (33%)                                    
   IV                                8 (73%)                                                         4 (67%)                                    
  Cancer-specific death              7 (64%)                                                         3 (50%)                                    0.64
  Median time to death (range)(mo)   5 (1--11)                                                       10 (8--14)                                 \-
  Dominant architectural pattern                                                                                                                **0.03**
   Reticular/cribriform              7/11 (64%)                                                      1/6 (17%)                                  
   Solid sheets/nests                1/11 (9%)                                                       5/6 (83%)                                  
  Rhabdoid cytology                                                                                                                             
   Focal to extensive                9/11 (82%)                                                      6/6 (100%)                                 0.51
  Presence of mucin                  3/11 (27%)                                                      3/6 (50%)                                  0.6
  Stromal myxoid change              6/11 (55%)                                                      2/6 (33%)                                  0.62
  Necrosis                           6/11 (55%)                                                      5/6 (83%)                                  0.33
  SMARCB1 loss (IHC)                 100%                                                            100%                                       \-
  OCT4 (IHC)                                                                                                                                    0.33
   (−) and 1+                        6/11 (55%)                                                      5/6 (83%)                                  
   2+ and 3+                         5/11 (45%)                                                      1/6 (17%)                                  

RMC: renal medullary carcinoma; IHC: immunohistochemistry.
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